<!DOCTYPE html>
<!--[if IE 9]><html lang="en-US" class="no-js ie-9"> <![endif]-->
<!--[if gt IE 9]><!--> <html lang="en-US" class="no-js"><!--<![endif]-->
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=0">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<title>Software as a Medical Device in Europe &ndash; New Regulatory Regime About to Enter into Force &ndash; (Part 6 of 6) | MoFo Life Sciences</title>
<meta name="description" itemprop="description" content>
<meta name="description" itemprop="keywords" content>
<link rel="canonical" href="https://lifesciences.mofo.com/topics/Software-as-medical-device-in-Europe-new-regulatory-regime-to-enter-into-force-part-6.html">
<link rel="stylesheet" id="validate-engine-css-css" href="css/blog-validationEngine.jquery.css" type="text/css" media="all">
<link rel="stylesheet" id="fontello-css" href="css/blog-embedded.css" type="text/css" media="all">
<link rel="stylesheet" id="mofo-fonts-css" href="css/blog-fonts.css" type="text/css" media="all">
<link rel="stylesheet" id="child-normalize-css" href="css/blog-normalize.css" type="text/css" media="all">
<link rel="stylesheet" id="child-foundation-css" href="css/blog-foundation.css" type="text/css" media="all">
<link rel="stylesheet" id="child-style-css" href="css/blog-style.css" type="text/css" media="all">
<link rel="stylesheet" id="child-jetpack-css" href="css/blog-jetpack.css" type="text/css" media="all">
<link rel="stylesheet" href="css/blog-custom-style.css" type="text/css" media="all">
<link rel="stylesheet" href="css/blog-print.css" type="text/css" media="all">
<link rel="stylesheet" href="css/blog-simple-nav.css" type="text/css" media="all">
<link rel="shortcut icon" href="https://media2.mofo.com/designimages/mofo-favicon-blue-180x180-2018.png" type="image/icon">
<link rel="shortcut icon" type="image/vnd.microsoft.icon" href="favicon.ico">
<link rel="icon" href="favicon.ico" type="image/icon">
<link rel="apple-touch-icon" type="image/png" href="https://media2.mofo.com/designimages/mofo-favicon-blue-180x180-2018.png"><!-- iPhone -->
<link rel="apple-touch-icon" type="image/png" sizes="72x72" href="https://media2.mofo.com/designimages/mofo-favicon-blue-180x180-2018.png"><!-- iPad -->
<link rel="apple-touch-icon" type="image/png" sizes="114x114" href="https://media2.mofo.com/designimages/mofo-favicon-blue-180x180-2018.png"><!-- iPhone4 -->
<link rel="stylesheet" href="css/jquery-ui.css">


    <!-- Google Tag Manager -->
    <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
    new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
    j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
    'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
    })(window,document,'script','dataLayer','GTM-T8Z9VLF');</script>
    <!-- End Google Tag Manager -->


<script defer src="js/all.js" crossorigin="anonymous"></script>

<!-- Jetpack Open Graph Tags -->
<meta property="og:type" content="website">
<meta property="og:title" content="Software as a Medical Device in Europe – New Regulatory Regime About to Enter into Force – (Part 6 of 6)">


																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																				<meta property="og:description" content="In+Part+6+of+our+series+of+consecutive+articles+on+the+reformed+regulatory+framework+under+the+EU+Medical+Device+Regulation+2017%2F745+%28%26ldquo%3BMDR%26rdquo%3B%29%2C+which+will+govern+medical+devices+software+%28%26ldquo%3BMDSW%26rdquo%3B%29+in+the+EU%2C+we+turn+to+the+transition+periods+certain+MDSW+can+benefit+from+before">
<meta property="og:url" content="https://lifesciences.mofo.com/topics/Software-as-medical-device-in-Europe-new-regulatory-regime-to-enter-into-force-part-6.html">
<meta property="og:site_name" content="MoFo Life Sciences">
<meta property="og:image" content="https://media2.mofo.com/images/mofolifesciences-eu.jpg">
<meta property="og:locale" content="en_US">



<style>
.svg-inline--fa {

    /*height: .8em;*/

    }
.svg-inline--fa {
    width: .475em;
}
 .sd-content a.nc-facebook-circled{
     color: #3b5998;
     font-size: 30px;
     }
     .sd-content a.nc-linkedin-circled{
     color: #0077b5;
     font-size: 30px;
     }
     .sd-content a.nc-twitter-circled{
     color: #00acee;
     font-size: 30px;
     }
     .sd-content a.nc-fa-envelope-square{
     color: #034193 ;
     font-size: 30px;
     }  
     .sd-content a.nc-fa-print{
     color: #000 ;
     font-size: 30px;
     }                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
     .sd-content a hover {
     }
     .sd-content i {
      margin: -4px;
     }
     #searchsubmit {
      font-size: 1em;
      border-radius: 3px;
      font-family: 'Oswald';
      text-transform: uppercase;
      letter-spacing: 2px;
      border-style: solid;
      border-width: 0;
      font-weight: 500;
    }
</style>

<meta name="google-site-verification" content="OD6S3RPM-cQOknAs1uXmBRvRJyh28rwkOoqdes47ZUE">
</head>
<body class="single single-post postid-574188201 single-format-standard full-width custom-background-empty">
    <!-- Google Tag Manager (noscript) -->
    <noscript>
      <iframe src="https://www.googletagmanager.com/ns.html?id=GTM-T8Z9VLF" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <!-- End Google Tag Manager (noscript) -->
    <script type="text/javascript"> 
<!-- 
var bb=new Image();var _ti=910;var _q="";var na=(navigator.appName=="Netscape");var ns=(navigator.appName.substring(0,9)=="Microsoft");var _qDate=new Date();var _r=(document.referrer.indexOf(getdomain(location))>-1?"":document.referrer);_q+="&5="+parseInt(_qDate.getTimezoneOffset());_q+="&35="+parseInt(_qDate.toString().indexOf("aylight")>-1?1:0);_q+="&6=574188201";_q+="&7=3262841";_q+="&8="+encodeURIComponent(document.location);_q+="&9="+encodeURIComponent(_r);_q+="&10="+encodeURIComponent(document.title);_q+="&11="+encodeURIComponent(navigator.userAgent);_q+="&12="+encodeURIComponent((na?navigator.language:navigator.userLanguage));_q+="&13="+((navigator.javaEnabled()?'1':'0'));if(document.cookie.indexOf("cc")==-1)document.cookie="cc=t;";_q+="&15="+((document.cookie.indexOf("cc")==-1)?"0":"1");_q+="&16="+encodeURIComponent((screen.width+'x'+screen.height));_q+="&17="+encodeURIComponent(((ns)?screen.colorDepth:screen.pixelDepth));_q+="&18="+encodeURIComponent(Math.random());_q+="&19="+_ti;bb.src="https://s.clickability.com/s?"+_q;
function setonclicks(a,b){var i=0;var retval=true;while(document.links[i]!=a){i++;}if(b.li[i])retval=b.li[i].oldonclick();bye(a);return retval;}
function newonld(){if(hasonload)oldonld();lnks=new Object();var sze=document.links.length;lnks.li=new Array(sze);for (var i=0; i<sze; i++){if(document.links[i].onclick){lnks.li[i]=document.links[i];lnks.li[i].oldonclick=document.links[i].onclick;}eval("document.links[i].onclick=function(){return setonclicks(this,lnks);}");}}function bye(a){if(a.href.toLowerCase().indexOf('http')!=0)return true;if(getdomain(location)==getdomain(a))return true;if(a.href.toLowerCase().indexOf('http')!=0)return true;var _qc="https://s.clickability.com/s?19=912";_qc+="&6=574188201";_qc+="&7=3262841";_qc+="&18="+encodeURIComponent(Math.random());_qc+="&100="+a.href;_qc+="&101="+encodeURIComponent(a.text);var cc=new Image();if(na){cc.src=_qc;pc(100);}else cc.src=_qc;return true;}function pc(a){d = new Date(); while (1){m =new Date(); df = m-d;if( df > a ) {break;}}}function getdomain(a){var i=a.host.indexOf(":");return (i>=0)?a.host.substring(0,i):a.host;}if(self['setupalready']){var dosetup = false;alert('There are two $imware.tracker calls on this page. Please alert Client Services');}else{var dosetup = true;var hasonload=false;}if(dosetup && ((window.screen)||((new Array()).toSource)||((new Array()).shift&&ns))&&(navigator.userAgent.indexOf('Mac')<0)){if(window.onload){oldonld=window.onload;hasonload=true;}window.onload=newonld;var setupalready = true;}//-->
</script><noscript>
<img alt="Clickability tracking pixel" width="1" height="1" src="https://s.clickability.com/s?19=990&amp;14=0&amp;6=574188201&amp;7=3262841&amp;25=0&amp;18=0.08181947055121119">
</noscript>

<div class="main-body-container" data-equalizer>    
<div class="nav_container">
	<a class="skip-link screen-reader-text" href="#content">Skip to content</a>  
        <div class="nav_wrap row ">
        	<div> <!-- add sticky here if needed -->
        	  <div>
                    <nav class="top-bar" data-topbar data-options="scrolltop:false;mobile_show_parent_link:false;">                  
                        <ul class="title-area">
	                        <li class="mofo-logo">
			                    <a href="https://www.mofo.com" title="Morrison & Foerster" target="_blank">
						<img src="https://media2.mofo.com/images/morrison-foerster-blog-logo.png" alt="logo">
			                    </a>
			                </li>
                            <li class="name">
                                <div class="header-title">
                                	<a href="index.html" title="MoFo Life Sciences" rel="home">
                                	                                	MoFo Life Sciences
                                	                                	</a>
                                </div>
                                                                <div class="header-subtitle">
                               		<span class="pms-7702c">Because No One is Immune to the Law</span>
                                </div>
                                                            </li>							
                            <!-- Remove the class "menu-icon" to get rid of menu icon. Take out "Menu" to just have icon alone -->
                                                    </ul>
</nav>
</div><!-- contain-to-grid sticky -->                
</div><!-- .row -->
</div>        
</div>
<!-- end .nav_container -->  


<div class="topnav" id="myTopnav">

<a href="index.html">Home</a>



<div class="divider"></div>
<div class="dropdown">

    <button class="dropbtn active">Topics 
     <i class="fa fa-caret-down"></i>
    </button>
    <div class="dropdown-content">

	
		 	<a href="topics_20.html">AI + Robotics</a>
		 	<a href="topics_5.html">Agtech</a>
		 	<a href="topics.html">Announcements</a>
		 	<a href="topics_2.html">Antitrust</a>
		 	<a href="topics_13.html">Asia</a>
		 	<a href="topics_9.html">Bioinformatics</a>
		 	<a href="topics_27.html">Biotech</a>
		 	<a href="topics_30.html">Blockchain</a>
		 	<a href="topics_6.html">CFIUS</a>
		 	<a href="topics_4.html">COVID-19</a>
		 	<a href="topics_16.html">Corporate + Venture Capital</a>
		 	<a href="topics_10.html">Data Analytics</a>
		 	<a href="topics_11.html">Digital Health</a>
		 	<a href="topics_23.html">Employment</a>
		 	<a href="topics_31.html">European Union</a>
		 	<a href="topics_18.html">FDA</a>
		 	<a href="topics_12.html">Financing</a>
		 	<a href="topics_29.html">Global</a>
		 	<a href="topics_21.html">Healthcare</a>
		 	<a href="topics_24.html">Intellectual Property</a>
		 	<a href="topics_3.html">Licensing + Commercial</a>
		 	<a href="topics_15.html">Litigation</a>
		 	<a href="topics_25.html">Medical Devices + Diagnostics</a>
		 	<a href="topics_17.html">Pharma</a>
		 	<a href="topics_19.html">Privacy + Data Security</a>
		 	<a href="topics_14.html">Product Liability + Class Action</a>
		 	<a href="topics_7.html">Rare Disease</a>
		 	<a href="topics_1.html">Regulatory</a>
		 	<a href="topics_26.html">Startup</a>
		 	<a href="topics_28.html">United Kingdom</a>
		 	<a href="topics_22.html">United States</a>
    </div>
  </div> 


<div class="divider"></div>
<a href="editors.html" class>Editors</a>


<div class="divider"></div>
<a href="about.html" class>About</a>


<div class="divider"></div>
<a href="javascript:void(0);" onclick="openSubscribeModal()" class>Subscribe</a>




<a href="javascript:void(0);" style="font-size:15px;" class="icon" onclick="myFunction()">&#9776;</a>
</div>
    
    


<script>
function printPage() {
  window.print();
}
</script>



<div class="content_container">
    <section class="content_wrap row" role="document">
        <div id="content" class="medium-8 large-8 columns" role="main">
            <article id="post-574188201" class="post-574188201 post type-post status-publish format-standard has-post-thumbnail hentry category-foreign-corrupt-practices-act">
                <header class="entry-header">
                    <div class="row blog-header">
                        <div class="columns medium-7 rockwell pms-7702c">
                            <em>April 13, 2021</em>
                            - <a href="topics_31.html" rel="category tag">European Union</a>, <a href="topics_25.html" rel="category tag">Medical Devices + Diagnostics</a>, <a href="topics_1.html" rel="category tag">Regulatory</a>
                        </div>
                        <div class="columns medium-5 social-jet">
                            <div class="sharedaddy sd-sharing-enabled">
                                <div class="robots-nocontent sd-block sd-social sd-social-icon sd-sharing">
                                    <h3 class="sd-title">Share This</h3>
                                            <div class="sd-content">
                                                <a title="Share on Facebook" class="nc-facebook-circled" href="http://www.facebook.com/sharer.php?u=https://lifesciences.mofo.com/topics/Software-as-medical-device-in-Europe-new-regulatory-regime-to-enter-into-force-part-6.html" target="_blank" onclick="javascript:window.open(this.href, '', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=350,width=600');return false;" rel="nofollow">
                                                    <i class="fab fa-facebook-square"></i>
                                                                                                    </a>
                                                <a href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://lifesciences.mofo.com/topics/Software-as-medical-device-in-Europe-new-regulatory-regime-to-enter-into-force-part-6.html&amp;title=Software as a Medical Device in Europe – New Regulatory Regime About to Enter into Force – (Part 6 of 6)&amp;summary=In Part 6 of our series of consecutive articles on the reformed regulatory framework under the EU Medical Device Regulation 2017/745 (MDR), which will govern medical devices software (MDSW) in the EU, we turn to the transition periods certain MDSW can benefit from before&amp;source=LinkedIn" onclick="javascript:window.open(this.href, '', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=350,width=600');return false;" rel="nofollow" class="nc-linkedin-circled" target="_blank" title="Share on LinkedIn">
                                                    <i class="fab fa-linkedin"></i>
                                                                                                    </a>
                                                <a href="share_113.html" onclick="javascript:window.open(this.href, '', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=350,width=600');return false;" rel="nofollow" target="_blank" class="nc-twitter-circled" title="Share on Twitter">
                                                    <i class="fab fa-twitter-square"></i>
                                                                                                    </a>
                                                <a href="mailto:recipient@domain.com?subject=MoFo Life Sciences&amp;body=Software as a Medical Device in Europe – New Regulatory Regime About to Enter into Force – (Part 6 of 6) - https://lifesciences.mofo.com/topics/Software-as-medical-device-in-Europe-new-regulatory-regime-to-enter-into-force-part-6.html" rel="nofollow" class="nc-fa-envelope-square" title="Email this page">
                                                  <i class="fas fa-envelope-square"></i>
                                                </a>
                                                <a href="#" onclick="printPage()" rel="nofollow" class="nc-fa-print" title="Print this page">
                                                  <i class="fas fa-print"></i>
                                                </a>
                                            </div>
                                </div>
                            </div>
                        </div>
                    </div>
                    <h1 class="entry-title">
                        Software as a Medical Device in Europe – New Regulatory Regime About to Enter into Force – (Part 6 of 6)</h1>
                </header>
                <!-- .entry-header -->
                <div class="entry-meta">
                    <div class="blog-author-meta subheader">			
                                                

                                                By: <a href="https://www.mofo.com/people/wolfgang-schonig.html" target="new">Wolfgang Schönig</a>, <a href="https://www.mofo.com/people/stephan-kress.html" target="new">Stephan Kreß</a>, <a href="https://www.mofo.com/people/robert-grohmann.html" target="new">Robert Grohmann</a>, and <a href="https://www.mofo.com/people/jacqueline-feigl.html" target="new">Jacqueline Madeleine Feigl</a>
                                                                    </div>
                </div>
                <div class="entry-content">
                                    <img width="300" class="alignright" src="https://media2.mofo.com/images/mofolifesciences-eu.jpg">
                                        <p>In Part 6 of our&nbsp;<a href="Software-as-a-Medical-Device-in-Europe--New-Regulatory-Regime-About-to-Enter-into-Force--Part-1-of-6.html" target="_blank">series of consecutive articles</a>&nbsp;on the reformed regulatory framework under the&nbsp;<a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02017R0745-20200424" target="_blank">EU Medical Device Regulation 2017/745</a>&nbsp;(&ldquo;<b>MDR</b>&rdquo;), which will govern medical devices software (&ldquo;<b>MDSW</b>&rdquo;) in the EU, we turn to the transition periods certain MDSW can benefit from before being required to fully comply with the MDR.</p>
<p>Transitional periods are provided in Article 120 MDR. In part due to the COVID-19 pandemic, the original text of Article 120 MDR has been corrected by two corrigenda (<a target="_blank" href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32017R0746R%2802%29">I</a>, <a target="_blank" href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32017R0746R%2803%29">II</a>) and another <a target="_blank" href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.2020.130.01.0018.01.ENG">Regulation</a> to avoid additional burdens to stakeholders and impasses in the supply of medical devices. The changes introduced by these amendments are twofold: On the one hand, the scope of the existing transitional periods was substantially changed and now includes more devices. On the other hand, the MDR now reflects the pushed-back applicability dates of the MDR and their influence on the transitional periods.</p>
<p>Due to the many amendments, however, the European legislator missed its aim to lay down clear and legible transitional rules. Therefore, the following article will decipher Article 120 MDR and provide an overview, which rules have to be observed when, as well as the prerequisites MDSW has to meet in order to benefit from the grace periods.</p>
<h4>1. INTRODUCTION: THE TERMINOLOGY OF ARTICLE 120 MDR</h4>
<p>The various transitional periods granted by Article 120 MDR allow for extended &ldquo;placing on the market,&rdquo; &ldquo;making available on the market,&rdquo; and &ldquo;putting into service&rdquo; of certain legacy MDSW, <i>i.e.</i>, MDSW that was in compliance with the provisions of the current&nbsp;<a href="https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:1993L0042:20071011:en:PDF" target="_blank">EU Medical Device Directive 93/42/EEC</a>&nbsp;(as amended by Directive&nbsp;2007/47/EC&nbsp;&ndash; &ldquo;<b>MDD</b>&rdquo;). Other than with physical medical devices, it can be challenging to determine when these actions take place. It is thus worthwhile to take a closer look at their definitions under the MDR.</p>
<p><i>Placing on the market</i> means the first making available of a device, other than an investigational device, on the EU market (Article 2 (28) MDR). It is subject to an ongoing debate whether MDSW is placed on the market as soon as it is offered for download through a website or an App Store or whether every license or access key to a MDSW granted to a user is placed on the market upon issuance. The latter option seems favorable due to the underlying rationale of the MDR. Most of the MDR provisions, including the transitional rules, were designed with physical medical devices in mind, and it is therefore common understanding that the placing on the market applies separately to each individual device. Translated to MDSW, this means that every license or access key will only be considered placed on the market once it is issued to the user.</p>
<p><i>Making available on the market </i>means any supply of a device, other than an investigational device, for distribution, consumption, or use on the EU market in the course of a commercial activity, whether in return for payment or free of charge (Article 2 (27) MDR). <i>Putting into service</i> means the stage at which a device, other than an investigational device, has been made available to the final user as being ready for use on the EU market for the first time for its intended purpose (Article 2 (29) MDR). Following the placing on the market through issuance of a license or access key to MDSW, it is then made available through the download by a user and put into service through its installation. These modalities therefore cover the maintenance of licenses to MDSW that were already granted to the user.</p>
<p>It must be mentioned that while some notified bodies back these conclusions, they are not set in stone, as courts have not yet decided on these issues.</p>
<h4>2. TRANSITIONAL PERIODS FOR UP-CLASSIFIED MDSW</h4>
<p>In <a target="_blank" href="Software-as-Medical-Device-in-Europe-New-Reg-Regime-to-Enter-into-Force-Part-3.html">Part 3</a> of this series, we discussed that it is to be expected that many MDSW that are currently classified in Class I under the MDD will be up-classified to Class IIa or higher under the MDR regime (&ldquo;<b>Up-classified MDSW</b>&rdquo;). Such MDSW will benefit from the transitional periods of the MDR in two ways. First, new licenses and access keys to Up-classified MDSW may be granted until May 26, 2024 (Article 120 (3) MDR). Second, licenses and access keys granted until May&nbsp;26, 2024, may be maintained until May 26, 2025 (Article 120 (4) MDR), <i>i.e.</i>, users may use, download, and install Up-classified MDSW that they already purchased.</p>
<p><b>a<i>. </i>Requirements for granting new licenses to Up-classified MDSW</b></p>
<p>For the aforementioned transitional periods to apply, the following requirements have to be met (<i>see </i><a target="_blank" href="https://ec.europa.eu/docsroom/documents/40324/attachments/1/translations/en/renditions/native">MDCG 2020-2</a> Guidance for further instructions; please note that the dates mentioned therein do not reflect the dates of the current version of the MDR):</p>
<ul>
<li>The MDSW needs to continue to <b>comply with the MDD</b>.</li>
</ul>
<ul>
<li>A valid <b>Declaration of Conformity </b>(&ldquo;<b>DoC</b>&rdquo;) complying with Annex VII of the MDD must be drawn before May 26, 2021. With the DoC, the manufacturer of the MDSW declares that it meets the relevant requirements of the MDD. Comprehensive instructions on the form, content, and handling of the DoC can be found in the MDCG 2020-2 Guidance, the <a target="_blank" href="https://eur-lex.europa.eu/legal-content/GA/TXT/?uri=CELEX:52016XC0726(02)">Blue Guide on the implementation of EU products rules 2016 (2016/C272/01)</a>, the standard EN ISO/IEC 17050-1/2, and the model declaration in Annex III of <a target="_blank" href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32008D0768">Decision No 768/2008/EC</a>.</li>
</ul>
<ul>
<li>The MDSW must not undergo <b>significant changes to its design or intended purpose</b> after May 26, 2021. It cannot be emphasized enough that this provision can have far‑reaching implications for the manufacturer&rsquo;s ability to benefit from the transitional period, as it covers a lot of changes that could be considered desirable or, in the worst case, even mandatory changes. While the MDR does not define when a change is &lsquo;significant,&rsquo; some meaningful guidance can be drawn from the <a target="_blank" href="https://ec.europa.eu/docsroom/documents/40301/attachments/1/translations/en/renditions/native">MDCG 2020-3 Guidance on Significant Changes</a> that leads the determination process through a series of flow charts. Additionally, the<i> </i><a target="_blank" href="https://www.johner-institut.de/blog/wp-content/uploads/2015/11/Recommendation-NB-MED-2_5-2_Rec2_Reporting_of_design_changes_and_changes_of_the_quality.pdf">NB-MED Coordination on Council Directives 90/385/EEC, 93/42/EEC, and 98/79/EC</a> as well as the <a target="_blank" href="http://www.doks.nbog.eu/Doks/NBOG_BPG_2014_3.pdf">NBOG&rsquo;s Best Practice Guide</a> should be considered. Following these guidelines, bug-fixes, security patches, and minor changes to non-critical parts of the user interface, such as spelling mistakes, will likely not be seen as significant. <i>Vice-versa</i>, changes to the intended user groups or changed indications, corrections of errors to minimize risks, changes to the user interface (like changing warning messages), or the use of a different runtime environment will likely be deemed significant (these examples are only for illustrative purposes and are not comprehensive).</li>
</ul>
<p>Any manufacturers of MDSW going this route are well advised to make themselves familiar with the guidance documents on significant changes. They should be aware that as MDSW by their very nature undergo a high volume of changes during their life cycle, it is likely that some of these changes could ultimately jeopardize the applicability of the transitional period.</p>
<p>This risk is accelerated by the new <a target="_blank" href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32019L0770">EU Directive on Digital Content and Services 2019/770</a>, which contains a mandatory obligation to update digital products in order to keep them in conformity with the underlying contract (Article 8 (2)). These obligations also apply to products, for which the consumer &ldquo;pays&rdquo; for with personal data (Article 3 (1)). Depending on the nature of the MDSW and the respective contract, changes required in this context can be of a kind that would be seen as significant under the MDR. As the Member States of the EU have to transpose these rules into national laws until July 1, 2021, these obligations will be applicable to manufacturers of MDSW very soon.</p>
<p><b>b. Maintaining existing licenses until May 26, 2025 (Article 120 (4) MDR)</b></p>
<p>Designed as a sell-off provision for physical medical devices, Article 120 (4) MDR allows for the continued making available on the market and putting into service until May 26, 2025, of legacy medical devices that were placed on the market prior to May 26, 2024. For MDSW, this means that licenses and access keys that were already issued before May 26, 2024, can be maintained for another year. In this timeframe, the manufacturer can give users who have already obtained a license or access key further access to the MDSW, allow the respective installations, and use and offer technical support.</p>
<h4>3. TRANSITIONAL PERIODS FOR SAME-CLASS MDSW</h4>
<p>Legacy MDSW that is classified as Class I under the MDD and which will remain in Class I under the MDR regime (&ldquo;<b>Same-class MDSW</b>&rdquo;) will have limited transitional options. Only licenses or access keys to Same-class MDSW granted before May 26, 2021, may be maintained until May 26, 2025 (Article 120 (4) MDR), <i>i.e.</i>, users may use, download, and install already obtained Same-class MDSW. This makes sense, as the main purpose for transitional periods must be found in the legislatures aim to avoid congestion of the bottleneck of certification, the notified bodies, and full compliance of Same-class MDSW with the MDR can be achieved by way of the continued possibility of self-certification of Class I devices, as we have shown in <a target="_blank" href="Software-as-Medical-Device-in-Eu--New-Reg-Enter-into-Force--Part-2-of-6.html">Part&nbsp;2</a> of this series.</p>
<p>To be on the safe side, manufacturers of Same-class MDSW should also consider not changing their product as long as use of already-issued licenses and access keys are required before full compliance with the MDR.</p>
<h4>4. TRANSITIONAL PERIODS FOR HIGHER-CLASS MDSW</h4>
<p>Even though most MDSW under the MDD was classified in Class I, some software for high-risk medical scenarios was already in Classes IIa to III (&ldquo;<b>Higher-class MDSW</b>&rdquo;). For example, MDSW intended to image <i>in vivo</i> distribution of radiopharmaceuticals was in Class IIa and MDSW controlling emitters of ionizing radiation for therapeutic interventional radiology was in Class IIb (<a target="_blank" href="https://ec.europa.eu/docsroom/documents/17921/attachments/1/translations/en/renditions/native">MEDDEV 2.1/6 Guidance of July 2016</a>, p. 16).</p>
<p>As Higher-class MDSW had to be certified by a notified body already under the MDD, the question whether new licenses and access keys may be granted depends on the continued validity of the certificate. Certificates to Higher-class MDSW certified prior to May 25, 2017, remain valid until the date indicated on the certificate.[1] Certificates to Higher-class MDSW certified after May 25, 2017, also remain valid until the indicated date but no longer than five years or until May 27, 2024, whichever is earlier. Accordingly, new licenses and access keys can be granted to customers as long as the MDSW certificate is valid but no longer than May 26, 2024 (Article 120 (2), (3) MDR).</p>
<p>As with Up-classified MDSW, the following requirements have to be met for the transitional periods to apply.</p>
<ul>
<li>The MDSW needs to continue to <b>comply with the MDD</b>.</li>
</ul>
<ul>
<li>The MDSW must not undergo <b>significant changes to its design or intended purpose</b> after May 26, 2021.</li>
</ul>
<p>Any licenses and access keys granted in the described timeframe may be maintained until May&nbsp;26, 2025 (Article 120 (4) MDR).</p>
<h4>5. MDR REQUIREMENTS TO BE MET DURING THE TRANSITIONAL PERIOD</h4>
<p>The transitional period must not be understood as a delay of application of the MDR. The following MDR provisions have to be complied with from May 26, 2021, in any scenario (Article&nbsp;120 (3) MDR):</p>
<ul>
<li>Post-market surveillance (Article 83 et seq, &ldquo;<b>PMS</b>&rdquo;): as we have shown in <a target="_blank" href="Software-as-a-Medical-Device-in-Europe--New-Regulatory-Regime-About-to-Enter-into-Force-Part-4-of-6.html">part 4 of this series</a>, manufacturers of MDSW need to establish a PMS system that systematically gathers records and analyzes relevant data on the quality performance of MDSW for its entire lifetime. As a result, the manufacturer needs to draw the necessary conclusions from the findings and implement preventive and corrective actions. Additionally, manufacturers of MDSW in Classes IIa to III have to prepare a Periodic Safety Update Report summarizing the results and conclusions out of the abovementioned aspects.</li>
</ul>
<ul>
<li>Vigilance (Article 87 et seq): Manufacturers of MDSW are required to investigate and report serious incidents and take and report field safety corrective actions with regard to their products. Furthermore, they have to report on trends concerning the frequency or severity of side effects that are documented in the MDSW informational material and the technical documentation. For further information on incident reporting, please refer to <a target="_blank" href="Software-as-a-Medical-Device-in-Europe--New-Regulatory-Regime-About-to-Enter-into-Force-Part-4-of-6.html">part 4 of this series</a>.</li>
</ul>
<ul>
<li>Registration of economic operators and of devices (Article 29 et seq): manufacturers will have to register their MDSW in accordance with the Unique Device Identifier (&ldquo;<b>UDI</b>&rdquo;) system that we have covered extensively in <a target="_blank" href="Software-as-medical-device-in-Europe--New-Regulatory-Regime-About-To-Enter-Into-Force--Part-5-of-6.html">Part 5 of our series</a>. In addition, they need to register themselves with a unique Single Registration Number (&ldquo;<b>SRN</b>&rdquo;) and, where applicable, the authorized representative and the importer. SRNs are assigned by the competent authorities in the EU member states. The registration will be carried out through the European Databank on Medical Devices (&ldquo;<b>EUDAMED</b>&rdquo;), which is in the process of being set up.</li>
</ul>
<ul>
<li>Market surveillance (Article 93): the provisions on market surveillance cover the duties and activities carried out by the competent authorities to ensure that medical devices do not pose significant risks to the health and safety of patients. It therefore does not directly apply to manufacturers of MDSW.</li>
</ul>
<h4>6. CONCLUDING REMARKS</h4>
<p>As it is to be expected that many Class I MDSW will be up-classified under the MDR, developers should be duly prepared to qualify for the transitional periods and put the delay to good use. First, they should assess any upcoming necessary changes to their products and plan on pushing back any of them that could be deemed significant, as they could lead to abrupt applicability of all relevant MDR requirements (although there may be cases where they are forced to implement changes under PMS). Second, manufacturers should familiarize themselves with their obligations regarding PMS, vigilance, and registration and be ready for full compliance from May 21, 2021. Third, they should start preparing for MDR certification as additional pressure on the Competent Authorities at the end of the transitional periods are predictable. Manufacturers should begin to, <i>inter alia</i>, collect clinical data on their MDSW, set up a Quality Management System, and draft Clinical Evaluation plans.</p>
<p>Timely preparation is of the essence as only an on-time certification can ensure a smooth transition into the new (delayed) framework.</p>
<hr width="33%" size="1">
<p>[1] In the rare case that a device has an EC-verification as set out in Annex IV to the MDD, it can only be placed on the market until May 27, 2022 (Article 120 (2) MDR).</p>
                        <div class="sharedaddy sd-sharing-enabled">
                            <div class="robots-nocontent sd-block sd-social sd-social-icon sd-sharing">
                                <h3 class="sd-title">Share This</h3>
                                        <div class="sd-content">
                                                <a title="Share on Facebook" class="nc-facebook-circled" href="http://www.facebook.com/sharer.php?u=https://lifesciences.mofo.com/topics/Software-as-medical-device-in-Europe-new-regulatory-regime-to-enter-into-force-part-6.html" target="_blank" onclick="javascript:window.open(this.href, '', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=350,width=600');return false;" rel="nofollow">
                                                    <i class="fab fa-facebook-square"></i>
                                                                                                    </a>
                                                <a href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://lifesciences.mofo.com/topics/Software-as-medical-device-in-Europe-new-regulatory-regime-to-enter-into-force-part-6.html&amp;title=Software as a Medical Device in Europe – New Regulatory Regime About to Enter into Force – (Part 6 of 6)&amp;summary=In Part 6 of our series of consecutive articles on the reformed regulatory framework under the EU Medical Device Regulation 2017/745 (MDR), which will govern medical devices software (MDSW) in the EU, we turn to the transition periods certain MDSW can benefit from before&amp;source=LinkedIn" onclick="javascript:window.open(this.href, '', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=350,width=600');return false;" rel="nofollow" class="nc-linkedin-circled" target="_blank" title="Share on LinkedIn">
                                                    <i class="fab fa-linkedin"></i>
                                                                                                    </a>
                                                <a href="share_113.html" onclick="javascript:window.open(this.href, '', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=350,width=600');return false;" rel="nofollow" target="_blank" class="nc-twitter-circled" title="Share on Twitter">
                                                    <i class="fab fa-twitter-square"></i>
                                                                                                    </a>
                                                <a href="mailto:recipient@domain.com?subject=MoFo Life Sciences&amp;body=Software as a Medical Device in Europe – New Regulatory Regime About to Enter into Force – (Part 6 of 6) - https://lifesciences.mofo.com/topics/Software-as-medical-device-in-Europe-new-regulatory-regime-to-enter-into-force-part-6.html" rel="nofollow" class="nc-fa-envelope-square" title="Email this page">
                                                  <i class="fas fa-envelope-square"></i>
                                                </a>
                                                <a href="#" onclick="printPage()" rel="nofollow" class="nc-fa-print" title="Print this page">
                                                  <i class="fas fa-print"></i>
                                                </a>
                                        
                                        </div>
                            </div>
                        </div>
                        <!-- .entry-content -->
                        <footer class="entry-meta">
                            <div class="entry-meta-footer">
                            </div>
                            <!-- end .entry-meta-footer -->
                        </footer>
                        <!-- .entry-meta -->
</div></article>
<!-- #post -->
                </div>
                <!-- #content -->
                <div id="secondary" class="medium-4 large-4 columns widget-area data-equalizer-watch" role="complementary">
                                        

        
  

                                                                                                                                                                                                                                                                                                                                                                   
<div class="text-center">
    <img src="https://media2.mofo.com/images/schonig_wolfgang_blog_150x150.png" alt>
</div>
<h5 class="text-center">Wolfgang Schönig</h5>
<div class="rockwell text-center subheader">
    Partner
</div>






<p class="bio">Wolfgang Schönig advises clients on IP aspects relating to transactions in, among others, the life sciences, AgTech and pharmaceuticals industry, as well as legal representation in IP disputes. His additional focus areas include research and development collaborations, complex licensing agreements, technology acquisitions, know-how protection strategies, and employee invention law.<a href="https://www.mofo.com/people/wolfgang-schonig.html" target="_blank"> More &rsaquo;</a>


</p>


        
  

                                                                                                                                                                                                                                                           
																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																						                        	                                      
<div class="text-center">
    <img src="https://media2.mofo.com/images/kress_stephan_blog_150x150.png" alt>
</div>
<h5 class="text-center">Stephan Kreß</h5>
<div class="rockwell text-center subheader">
    Counsel
</div>






<p class="bio">Stephan is counsel at Morrison &amp; Foerster&rsquo;s German office in Berlin. As a member of the technology transactions group, he focuses on advising major German and international clients with regard to drafting and negotiating complex technology-related agreements and on matters concerning cloud computing, software, e/m-commerce, digital media, intellectual property rights, consumer rights, electronic communication, big data and cyber security requirements.

Stephan is specialized in drafting<a href="https://www.mofo.com/people/stephan-kress.html" target="_blank"> More &rsaquo;</a>


</p>


        
  

                                                                                                                                                                                                                                                           
																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																									                        	                                      
<div class="text-center">
    <img src="https://media2.mofo.com/images/grohmann_robert_blog_150x150.png" alt>
</div>
<h5 class="text-center">Robert Grohmann</h5>
<div class="rockwell text-center subheader">
    Senior Associate
</div>






<p class="bio">Robert is a senior associate at Morrison &amp; Foerster&rsquo;s German office in Berlin. As a member of the technology transactions group, he focuses on advising domestic and foreign companies and startups in all areas of technology and IP law, including patent and software licensing, employee inventions law, as well as know-how protection. Moreover, Robert&rsquo;s expertise encompasses the judicial and extra-judicial representation in matters of<a href="https://www.mofo.com/people/robert-grohmann.html" target="_blank"> More &rsaquo;</a>


</p>


        
  

                                                                                                   
																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																									                        	                                      
<div class="text-center">
    <img src="https://media2.mofo.com/images/feigl_jacqueline_blog_150x150.png" alt>
</div>
<h5 class="text-center">Jacqueline Madeleine Feigl</h5>
<div class="rockwell text-center subheader">
    Associate
</div>






<p class="bio">As a member of the technology transactions group, Jacqueline advises domestic and foreign companies and startups in all areas of technology and IP law, including patent and software licensing, employee inventions law, and know-how protection. Her experience encompasses domestic and cross-border patent litigation and other technology-related disputes. Jacqueline is also well versed in German and European trademark and advertising law.

Jacqueline focused on intellectual property<a href="https://www.mofo.com/people/jacqueline-feigl.html" target="_blank"> More &rsaquo;</a>


</p>


<aside id="black-studio-tinymce-3" class="widget widget_black_studio_tinymce">
    <div class="textwidget">
        <div class="gray-sidebar">
            <h5>Stay Connected </h5>
                                        <a title="Connect via LinkedIn" class="nc-linkedin-circled" href="https://www.linkedin.com/company/morrison-&amp;-foerster-llp" target="_blank">
                        <i class="icon-linkedin-circled footer-icons black85"></i>
                    </a>
                                        <a title="Connect via Twitter" class="nc-twitter-circled" href="https://twitter.com/MoFoLLP" target="_blank">
                        <i class="icon-twitter-circled footer-icons black85"></i>
                    </a>
                                        <a title="Connect via RSS" class="nc-rss" href="rss" target="_blank">
                        <i class="icon-rss footer-icons black85"></i>
                    </a>
                            </div>
    </div>
</aside>
<aside id="search-2" class="widget widget_search">
    <form role="search" method="get" id="searchform" action="/search/">
        <div class="row collapse">
            <div class="medium-12 large-12 columns">
                <input type="text" value name="s" id="s">
                    <div class="search-icon">
                        <i class="icon-search footer-icons pms-7702c"></i>
                    </div>
                    <input type="submit" id="searchsubmit" value="Search" class="search-btn">
                    </div>
</div>
</form>
</aside>
<aside id="categories-2" class="widget widget_categories">
    <h6 class="widget-title">Topics</h6>
            <label class="screen-reader-text" for="cat">Topics</label>
            <select name="cat" id="cat" class="postform">
                <option value="-1">Topics</option>
                                                                                                                                                <option class="level-0" value="1457511">AI + Robotics</option>
                                                                                                <option class="level-0" value="1457521">Agtech</option>
                                                                                                <option class="level-0" value="1457691">Announcements</option>
                                                                                                <option class="level-0" value="1462201">Antitrust</option>
                                                                                                <option class="level-0" value="1457531">Asia</option>
                                                                                                <option class="level-0" value="1468521">Bioinformatics</option>
                                                                                                <option class="level-0" value="1456751">Biotech</option>
                                                                                                <option class="level-0" value="1458171">Blockchain</option>
                                                                                                <option class="level-0" value="1458511">CFIUS</option>
                                                                                                <option class="level-0" value="1462211">COVID-19</option>
                                                                                                <option class="level-0" value="1457541">Corporate + Venture Capital</option>
                                                                                                <option class="level-0" value="1458861">Data Analytics</option>
                                                                                                <option class="level-0" value="1465651">Digital Health</option>
                                                                                                <option class="level-0" value="1458521">Employment</option>
                                                                                                <option class="level-0" value="1457551">European Union</option>
                                                                                                <option class="level-0" value="1459381">FDA</option>
                                                                                                <option class="level-0" value="1457561">Financing</option>
                                                                                                <option class="level-0" value="1459511">Global</option>
                                                                                                <option class="level-0" value="1459951">Healthcare</option>
                                                                                                <option class="level-0" value="1457581">Intellectual Property</option>
                                                                                                <option class="level-0" value="1457591">Licensing + Commercial</option>
                                                                                                <option class="level-0" value="1457601">Litigation</option>
                                                                                                <option class="level-0" value="1459061">Medical Devices + Diagnostics</option>
                                                                                                <option class="level-0" value="1457631">Pharma</option>
                                                                                                <option class="level-0" value="1457641">Privacy + Data Security</option>
                                                                                                <option class="level-0" value="1457651">Product Liability + Class Action</option>
                                                                                                <option class="level-0" value="1465361">Rare Disease</option>
                                                                                                <option class="level-0" value="1459071">Regulatory</option>
                                                                                                <option class="level-0" value="1459521">Startup</option>
                                                                                                <option class="level-0" value="1462611">United Kingdom</option>
                                                                                                <option class="level-0" value="1457671">United States</option>
                                                            </select>
            <script type="text/javascript">
                /* <![CDATA[ */
                (function() {
                var dropdown = document.getElementById( "cat" );
                function onCatChange() {
                if ( dropdown.options[ dropdown.selectedIndex ].value > 0 ) {
                location.href = "/topics/?c=" + dropdown.options[ dropdown.selectedIndex ].value;
                }
                }
                dropdown.onchange = onCatChange;
                })();
                /* ]]> */
            </script>
</aside>
<aside class="widget widget_recent_entries">
    <h6 class="widget-title">Recent Posts</h6>
            <ul>
                                                    <li>
                        <a href="eu-in-vitro-diagnostic-regulation-entered-into-force-part-3-of-3.html">EU: IN VITRO DIAGNOSTIC REGULATION ENTERED INTO FORCE (PART 3 OF 3)</a>
                    </li>
                                                                    <li>
                        <a href="fda-will-once-again-accept-pre-submissions-for-all-in-vitro-diagnostic-tests.html">FDA Will Once Again Accept Pre-Submissions for All In Vitro Diagnostic Tests</a>
                    </li>
                                                                    <li>
                        <a href="eu-in-vitro-diagnostic-regulation-entered-into-force--part-2-of-3.html">EU: IN VITRO DIAGNOSTIC REGULATION ENTERED INTO FORCE  (PART 2 OF 3) </a>
                    </li>
                                                                    <li>
                        <a href="eu-in-vitro-diagnostic-regulation-entered-into-force--part-1-of-3.html">EU: IN VITRO DIAGNOSTIC REGULATION ENTERED INTO FORCE  (PART 1 OF 3) </a>
                    </li>
                                                                    <li>
                        <a href="senators-call-for-report-on-state-of-psychedelic-research.html">Senators Call for Report on State of Psychedelic Research</a>
                    </li>
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </ul>
</aside>
<aside id="black-studio-tinymce-6" class="widget widget_black_studio_tinymce">
     <style>

address {
  font-style: normal;
  margin-bottom: 14px;
  margin-left: 10px;
}

address .contact  {
  display: block;
  
}

address .email a:hover {
  color: #0078a0;
}

.location, .attorney, .email {
  display: block;

}

address .email a {
color: #5e5f61;
}

.location {
  font-weight: 900;
  font-family: 'Oswald', sans-serif;
  text-transform: uppercase;
}

.contact-title {
  font-family: 'Oswald', sans-serif;
  font-size: .825em;
  background-color: #eeeeee;
  padding: .8em;
  letter-spacing: 2px;
  text-transform: uppercase;
  margin-bottom: 10px;
  display: block;
  font-weight: 900;
}

</style>




</aside>
                </div>
                <!-- #secondary -->
</section>
<!-- end .content-wrap -->
        </div>
        <!-- end .content_container -->
        <div style="display:none;" id="dialog-message" title="Email Disclaimer">
	<p>Unsolicited e-mails and information sent to Morrison &amp; Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison &amp; Foerster. If you are not already a client of Morrison &amp; Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.</p>
</div>
<div class="footer_container">
    <footer class="footer_wrap row" role="contentinfo">
        <div id="footer" class="row" role="contentinfo">
            <div class="columns medium-12 footer-nav-wrapper">
                <div class="footer-nav">
                    <ul>
                                                <li class="divider"></li>
                        <li id="menu-item-3395" class="menu-item menu-item-footer menu-item-terms-of-use">
                            <a target="_blank" href="https://www.mofo.com/about/terms-notices.html">Terms of Use</a>
                        </li>
                                                <li class="divider"></li>
                        <li id="menu-item-3395" class="menu-item menu-item-footer menu-item-cookies">
                            <a target="_blank" href="https://www.mofo.com/about/cookies.html">Cookies</a>
                        </li>
                                                <li class="divider"></li>
                        <li id="menu-item-3395" class="menu-item menu-item-footer menu-item-privacy-policy">
                            <a target="_blank" href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>
                        </li>
                                                <li class="divider"></li>
                        <li id="menu-item-3395" class="menu-item menu-item-footer menu-item-disclaimer">
                            <a target="_blank" href="https://www.mofo.com/special-content/blog-disclaimer/">Disclaimer</a>
                        </li>
                                                <li class="divider"></li>
                        <li id="menu-item-3395" class="menu-item menu-item-footer menu-item-attorney-advertising">
                            <a target="_blank" href="https://www.mofo.com/about/attorney-advertising.html">Attorney Advertising</a>
                        </li>
                        </ul></div>
                </div>
                <div class="columns medium-12 text-center">
                    <p class="copyright">&copy;1996-2022 Morrison &amp; Foerster LLP. <span class="show-for-small"><br></span>All Rights Reserved.</p>
                </div>
                <div class="medium-2 medium-centered columns">
                                                            <a title="Connect via LinkedIn" class="nc-linkedin" href="https://www.linkedin.com/company/morrison-&amp;-foerster-llp" target="_blank">
                        <i class="icon-linkedin-circled footer-icons pms-7702c"></i>
                    </a>
                                                            <a title="Connect via Twitter" class="nc-twitter" href="https://twitter.com/MoFoLLP" target="_blank">
                        <i class="icon-twitter-circled footer-icons pms-7702c"></i>
                    </a>
                                                            <a title="Connect via RSS" class="nc-rss" href="rss" target="_blank">
                        <i class="icon-rss footer-icons pms-7702c"></i>
                    </a>
                                    </div>
                                            </div>
</footer>
<!-- .row -->
</div>
<!-- end #footer_container -->
<div id="backtotop" class="hvr-fade">
    <span class="genericon genericon-collapse"></span>
</div>
<!-- #backtotop -->

</div>
     <div class="textwidget">
        <div id="subscribe-modal" class="reveal-modal" data-reveal aria-labelledby="subscribe-modal" aria-hidden="true" role="dialog">
            <aside class="widget widget_black_studio_tinymce">
                <div class="textwidget newsletter_subscribe">
                    <div>
                        <h5>Subscribe</h5>
                                <p>Never miss a post from MoFo Life Sciences. Enter your email below to stay up-to-date.</p>
                    </div>
                </div>
                            </aside>
            <p>
                <div class="resultLabel"></div>
                <div class="widget_wysija_cont shortcode_wysija newsletter_subscribe">
                                   <iframe src="https://www2.mofo.com/l/323401/2020-09-03/621wk" width="100%" height="450" type="text/html" frameborder="0" allowTransparency="true" style="border: 0"></iframe>
                                                </div>
                    <a class="close-reveal-modal" onClick="closeSubscriptionModal()" aria-label="Close"></a>
</p></div>
</div>



<script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');
  ga('create', 'UA-12456654-15', 'auto');   ga('send', 'pageview');
</script>

<script type="text/javascript"> 
/*<![CDATA[*/ 
(function() { 
var sz = document.createElement('script'); sz.type = 'text/javascript'; sz.async = true; 
sz.src = '//siteimproveanalytics.com/js/siteanalyze_59840.js'; 
var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(sz, s); 
})(); 
/*]]>*/ 
</script>




<script>
  function myFunction() {
    var x = document.getElementById("myTopnav");
    if (x.className === "topnav") {
      x.className += " responsive";
    } else {
      x.className = "topnav";
    }
  }
  </script>
  
  
  <script>
  

function openSubscribeModal() {
console.log('openSubscribeModal')
  var m = document.getElementById('subscribe-modal');
  m.style.visibility = 'visible';
  m.style.display = 'block';
  }
  
  function closeSubscriptionModal() {
    var m = document.getElementById('subscribe-modal');
  m.style.visibility = 'hidden';
  m.style.display = 'none';
  }

  </script>
  

</body>
</html>